Dr Javier Cortés talks to ecancer at the 2013 European Cancer Congress about the process of creating biosimilar drugs for approval in Europe.

Dr Cortés explains that biosimilar drugs are genetically similar to already approved drugs but are produced at a much lower cost and can be distributed on a much larger scale.